Notusin

Quick links to important sections

Notusin

Treatment option: Cough

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Notusin

Property Description
Active ingredient Dextromethorphan Hydrobromide
Form Oral liquid, tablet, lozenge, capsule
Pharmacological class Antitussive (Cough Suppressant)
Common use Symptomatic relief of dry, non-productive cough
Origin Synthetic compound (Morphinan derivative)

What Type of Medicine is Notusin? (Definition and Classification)

Notusin is a medicinal product whose core active component is Dextromethorphan Hydrobromide, a substance classified pharmacologically as a centrally acting antitussive, or cough suppressant. Dextromethorphan is utilized to temporarily relieve cough caused by the common cold and other conditions. This confirms the medicine's primary role in providing short-term comfort from bothersome coughing. The active substance is structurally derived from the morphinan chemical class, making it a synthetic analog; however, it functions as a non-opioid centrally acting agent for cough relief.

Composition and Origin: Is Dextromethorphan Synthetic? (Substance and Form)

The active substance, Dextromethorphan Hydrobromide, is a synthetic compound manufactured as the hydrobromide salt. It is administered via the oral route and is available in several forms, including syrups, oral solutions, extended-release suspensions, lozenges, and tablets. The composition generally consists of the active ingredient and an excipient base, such as an aqueous vehicle for liquid forms or solid binders for tablets. Dextromethorphan Hydrobromide is categorized for its general antitussive properties.

What is the General Purpose of Notusin? (Action and Benefit)

The general purpose of Notusin is to provide temporary, symptomatic relief specifically for a non-productive, or dry, cough. This medicine is typically sought when the patient experiences frequent, irritating coughing fits that offer no physiological benefit. The mechanism involves influencing the cough center located in the central nervous system, thereby working to elevate the cough threshold. By acting on this neurological control point, the medicine decreases the overall sensitivity to irritants, consequently reducing the frequency and severity of unnecessary coughing fits.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Notusin?

Possible Side Effects and Safety Information for Notusin

The safety profile of Notusin (Dextromethorphan Hydrobromide) is characterized by a range of officially documented effects, which regulatory agencies classify by frequency and the body systems involved.

Adverse reactions are primarily linked to the Nervous System and Gastrointestinal System.

Classification Adverse Reactions System Organ Class
Uncommon Drowsiness (Somnolence), Dizziness, Nausea, Vomiting, Gastrointestinal discomfort Nervous System / Gastrointestinal Disorders
Not Known Agitation, Confusional state, Insomnia, Serious skin reactions (e.g., Urticaria, Angioedema), Seizure, Respiratory depression Psychiatric / Skin / Respiratory Disorders

Serious Adverse Reactions and Constraints

The regulatory safety profile highlights several serious risks, particularly those related to drug interactions and metabolism. The risk of Serotonin Syndrome is explicitly documented, arising from co-administration with serotonergic agents, such as MAOIs. Respiratory Depression and central nervous system toxicity are noted toxic effects, especially in the event of exaggerated exposure.

Official labeling includes constraints for specific populations. Caution is advised for individuals with hepatic impairment (liver issues), as Dextromethorphan is extensively metabolized by the liver. Patients identified as poor CYP2D6 metabolizers are also at increased risk for toxic effects and severe adverse reactions. Furthermore, regulatory documents specify that prolonged use, even at therapeutic levels, carries a documented risk for the development of drug dependence.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with this class of medication is a serious event that can be potentially life-threatening and requires immediate emergency medical attention. The official regulatory documents define the overdose profile primarily through effects on the central nervous system (CNS) and the respiratory system.

Documented Overdose Presentations

The clinical manifestations of an overdose, as described in authorized labeling, typically involve severe CNS depression. The physiological systems most affected are the Central Nervous System and the Respiratory System. Overdose presentations may include:

  • Profound sedation and marked drowsiness
  • Respiratory depression, characterized by slow, shallow, or labored breathing
  • Ataxia (unsteadiness or loss of coordination)
  • Dizziness or unsteadiness
  • Progression to coma (loss of consciousness)

Required Emergency Actions

In the event of an overdose (ingestion of quantities substantially greater than the recommended dose), immediately seek emergency medical attention by contacting local emergency services. Emergency response statements in official documents mandate immediate treatment with general symptomatic and supportive measures.

Management is primarily supportive, focusing on maintaining adequate ventilation and circulatory function. The regulatory profile notes that there is no specific antidote available to reverse all effects of this drug's toxicity. Depending on the timing of ingestion, gastrointestinal decontamination (such as activated charcoal) may be considered by healthcare professionals. Continuous monitoring of vital signs is essential during the management of overdose.

Therapeutic Uses of Notusin

Targeting Acute, Non-Productive Coughs in Respiratory Illness

Notusin is commonly applied for the symptomatic relief of the dry, non-productive cough commonly associated with conditions characterized by periods of heightened symptoms, such as the common cold and influenza. This medication is relevant in clinical contexts involving irritative states, where the symptoms become more disruptive. Dextromethorphan is used to temporarily relieve cough caused by the common cold, the flu, or other conditions. The therapeutic use is relevant for symptoms such as frequent, irritating coughing fits, and discomfort linked to minor throat or bronchial irritation.

Providing Comfort and Supporting Undisrupted Rest

The primary therapeutic support offered is short-term symptomatic assistance against the frequent, irritating coughing fits that may interfere with daily comfort and sleep. By easing the overall symptom load, Notusin supports improved comfort during periods of heightened symptoms. It is relevant when the acute manifestations may interfere with the ability to achieve rest, providing supportive relief during difficult episodes.

“The medication is often used during phases when symptoms become more noticeable and supportive symptomatic assistance is needed.”

Quick Fact: Relief for Irritation-Induced Cough

The medication's primary role is managing symptoms related to physical discomfort, which may assist with maintaining a sense of stability and supports general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

This information is based strictly on the official eligibility profiles documented by government regulatory agencies for products containing the active ingredient, Codeine.

Populations Who Must Not Use Notusin (Contraindications)

Notusin is contraindicated for use in the following populations and conditions, based on official labeling from regulatory authorities:

Contraindicated Group Condition/Age Restriction
Pediatric All children under 12 years of age.
Post-Surgical Pediatric Adolescents under 18 years of age following tonsillectomy and/or adenoidectomy.
Metabolic Patients who are CYP2D6 ultra-rapid metabolizers (high risk for toxicity).
Respiratory Patients with significant respiratory depression or acute bronchial asthma in unmonitored settings.
Gastrointestinal Patients with known or suspected gastrointestinal obstruction, including paralytic ileus.

Restricted or Not Recommended Use

  • Breastfeeding Mothers: Use is not recommended or contraindicated due to the risk of serious adverse reactions in the infant, as the medicine can pass into breast milk.
  • Pregnancy: Prolonged use may cause Neonatal Opioid Withdrawal Syndrome in the newborn.
  • Comorbidities: Caution is required in patients with severe hepatic or renal impairment, as well as in the elderly population, due to increased susceptibility to side effects.

Regulatory agencies impose these stringent eligibility rules to mitigate the risk of serious breathing problems and opioid toxicity, which are significantly higher in these excluded populations.

What should I know about interactions with other medicines?

Notusin Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Notusin (Dextromethorphan Hydrobromide), based on regulatory labeling from authorities such as the FDA and EMA. This information strictly details known interactions and prohibitions.


Formal Contraindicated Combinations

The most critical restriction is the formal prohibition of combining Notusin with Monoamine Oxidase Inhibitors (MAOIs), a class of medication for psychiatric conditions. This combination is contraindicated due to the high risk of a serious adverse event known as Serotonin Syndrome. A mandatory 14-day period must elapse after discontinuing an MAOI before Notusin can be taken.


Metabolic and Pharmacodynamic Interactions

Notusin's primary metabolism is via the CYP2D6 liver enzyme. Concomitant use with potent CYP2D6 inhibitors (e.g., Fluoxetine, Quinidine) is officially documented to significantly increase Notusin's plasma concentrations, which can lead to prolonged or exaggerated effects.

Regulatory documentation also highlights pharmacodynamic risks with other serotonergic agents (e.g., SSRIs, SNRIs) and the herbal product St. John's wort, as these combinations increase the overall serotonergic load. Furthermore, co-administration with alcohol or other CNS depressants is documented to result in additive depressant effects.

Mechanism of Action

Central Receptor Targeting and Signal Modulation

Notusin's mechanism of action is exclusively central, targeting neurological structures within the brainstem. The active component, Dextromethorphan, engages in a dual molecular interaction: it functions as an agonist at the Sigma-1 (sigma1) receptor while simultaneously acting as an uncompetitive antagonist that blocks the ion channel pore of the NMDA receptor. This targeted receptor modulation reduces excitatory signaling within the central nervous system (CNS).

️ Increasing the Central Cough Threshold

The molecular action on CNS receptors triggers a functional sequence within the medullary cough center. By stabilizing the neural pathway that controls the reflex, the mechanism increases the central cough threshold. This systemic effect means the afferent signal required to initiate the efferent reflex command is increased, resulting in an alteration of the neurological command threshold for reflex execution.

Mechanistic Constraints of Reflex Suppression

The mechanism is physiologically constrained because it operates solely through reflex suppression centrally. This means the mechanism is physiologically irrelevant when simultaneous airway clearance is required. Furthermore, the final strength of the NMDA antagonism is linked to the conversion of the drug into its active metabolite by the variable CYP2D6 enzyme, which can influence the resulting physiological effect.

Dosage and Administration Information

How to Use Notusin

The administration of Notusin (Dextromethorphan Hydrobromide) is structured around standard, label-based instructions that govern its high-level use in clinical practice, focusing strictly on approved quantity and timing. The medication is approved exclusively for oral administration across all its available forms, which include immediate-release tablets, capsules, lozenges, and oral liquids.


Standard Dosage and Frequency

For adults and children 12 years and older, the standard immediate-release dose is typically 10 mg to 20 mg taken every 4 hours, or 30 mg taken every 6 to 8 hours. Extended-release liquid formulations are administered at a dose of 60 mg every 12 hours. It is an explicit administration rule that the total amount of Dextromethorphan must not exceed 120 mg within a 24-hour period.


Administration Requirements

  • Measurement: To ensure the correct dose, particularly with liquid forms, an accurate measuring device must be used, as household spoons are unreliable.
  • Preparation: Oral suspensions must be shaken well before use to distribute the active ingredient evenly. Solid dosage forms like lozenges must be allowed to dissolve slowly in the mouth and should not be swallowed whole.
  • Timing: The medicine is generally taken with or without food. Administration with food or milk may be advised if gastric discomfort occurs.

Population and Duration Rules

Usage guidelines indicate that Notusin is not recommended for children under 4 years of age. Dosage adjustments are provided for children between 4 and 12 years. Use is intended for temporary, short-term relief. Patients are instructed that if cough symptoms persist for more than seven days, medical consultation is required. Furthermore, to prevent exceeding the maximum daily intake, patients must not take more than one product containing Dextromethorphan simultaneously.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Notusin

Research was studied for the use of Notusin in individuals with conditions characterized by fluctuating or episodic manifestations. These investigations involve different types of studies, including randomized trials and observational settings, which are designed to collect data on patient experiences and monitor changes.

The studies often focus on outcomes describing episodic or acute changes and are applied in research contexts involving fluctuating or unstable symptoms. The overall evidence contributes to understanding symptom patterns and how patients reported their experience. However, these findings describe patterns observed in the studies and do not determine whether an individual will respond similarly. Research provides context but not individual predictions.


Conditions Presenting with Cycles of Heightened Symptom Activity

Notusin was studied for its use in conditions involving periods of heightened symptoms that are marked by functional limitations. The research explored outcomes related to systemic or functional imbalance over defined time intervals.

In some studies, findings suggested that Notusin was associated with measured changes in outcomes reflecting daily functioning or activity level during the study period compared to a placebo. These findings contribute to understanding symptom patterns in these areas.

However, data are still emerging, and follow-up durations were limited. Long-term effects are not fully established, and certainty remains low for long-term outcomes. Furthermore, comparative evidence is lacking between Notusin and other treatments that might be used for these conditions.


Conditions Involving Outcomes Linked to Physical Discomfort

Studies have also examined Notusin in the context of conditions associated with acute or disruptive episodes, particularly those where patients experience outcomes related to physical discomfort. The data show patterns related to how symptom intensity or variability was measured in these short-term studies, compared to observations in the control groups.

It is important to understand the limitations: the results apply only to the populations studied, and in many cases, sample sizes were modest. The findings describe group patterns, not personal outcomes; research does not determine whether an individual will respond similarly. Research is ongoing to fill these knowledge gaps and contribute to the broader evidence landscape.

Frequently Asked Questions (FAQ)

Common questions about Notusin (FAQ)


Q: How quickly should I expect Notusin to start working?

According to official product information, the active ingredient in Notusin (Dextromethorphan) is typically absorbed quickly. Its relieving effects usually begin within 15 to 30 minutes after the medicine is taken by mouth.


Q: How long does the effect of one dose of Notusin usually last?

The duration of the medication’s effect can vary based on the specific formulation of Notusin being used (such as immediate-release versus extended-release). Official regulatory information indicates that the therapeutic effect typically lasts approximately 3 to 8 hours.


Q: What happens if I miss a dose of Notusin?

If the medicine is taken on a regular schedule and a dose is missed, taking it as soon as remembered is generally suggested. However, if it is almost time for the next scheduled dose, regulatory guidance suggests skipping the missed dose completely. Taking a double dose to compensate for a missed one is not recommended.


Q: How long is Notusin typically recommended for use?

Notusin is officially intended for temporary, short-term use to relieve coughing symptoms. Regulatory labeling advises that if a cough lasts for more than 7 days or if it is a chronic cough (e.g., related to asthma or smoking), medical consultation is required.


Q: Is it possible to become dependent on Notusin?

Yes, the official regulatory safety profile for Notusin’s active ingredient states there is a documented risk for the development of drug dependence with prolonged use, even when the medicine is taken at therapeutic levels.


Q: Is it true that Notusin can sometimes cause headaches?

While headaches are not consistently listed as an officially common side effect across all Dextromethorphan labels, the medicine works on the central nervous system ( CNS). The CNS action is associated with other effects like dizziness and nervousness. If persistent or bothersome, seeking guidance from a healthcare provider is appropriate.


Q: How soon after stopping Notusin will the drug be completely out of my system?

The time required for the body to eliminate the medicine depends on its half-life, which can be variable. The half-life of Dextromethorphan is typically short (2 to 4 hours) for most people, but it can be longer (up to 24 hours) in individuals who metabolize the drug slowly.


Q: Can Notusin be taken on an empty stomach?

Regulatory information indicates that Notusin can generally be taken with or without food. Official sources note that administration with food or milk may be considered if gastric discomfort or upset occurs.


Q: Can Notusin interact with common over-the-counter cold medicines?

Yes, regulatory labeling warns against taking more than one product containing Dextromethorphan at the same time. Additionally, caution is advised when combining Notusin with other CNS depressants (medicines that slow brain activity), which can often be found in various cold and flu preparations.


Q: Are there any natural supplements that should not be taken with Notusin?

Official drug interaction information specifically lists the herbal product St. John’s wort as one that may increase the overall serotonergic load when combined with Dextromethorphan. This risk is typically managed by a healthcare provider.


Q: Is it better to take Notusin in the morning or at night?

Regulatory directions for Notusin do not specify an optimal time of day for all users, as it can typically be taken at any time. Adherence to the frequency and timing specified on the product packaging or by a healthcare professional is important.


Q: Why might Notusin cause dizziness in some people?

Notusin’s active component is a centrally acting agent that affects neurological structures in the brainstem. Side effects such as dizziness or drowsiness are linked to these central nervous system effects on signaling.


Q: Can Notusin affect sleep patterns?

Yes, the regulatory safety profile for the active ingredient includes Insomnia (difficulty sleeping) as a documented adverse reaction. Medical consultation is appropriate if persistent changes to sleep patterns are noticed while using Notusin.


Q: Does taking Notusin affect your ability to drive?

Because Notusin can cause side effects like dizziness or drowsiness, it may impair an individual's ability to think or react. Regulatory warnings advise that activities requiring mental alertness, such as driving or operating heavy machinery, should be avoided until the individual knows how the medicine affects them.


Q: Is Notusin effective for chronic conditions or only short-term use?

Notusin is officially approved to provide temporary, symptomatic relief for minor cough. Regulatory labeling cautions against using it for chronic cough (such as one associated with smoking or emphysema). Not recommended for chronic cough unless under professional guidance.


Q: What is the typical time frame for seeing the full benefit of Notusin?

Notusin is designed to provide temporary, symptomatic relief of cough. The full benefit is generally observed within the first few doses. If the cough persists or worsens after seven days of use, regulatory guidelines specify that medical consultation is appropriate.


Q: Why do some people report feeling jittery after taking Notusin?

Official regulatory safety information includes Agitation and Nervousness as documented adverse reactions to Dextromethorphan. These effects are central nervous system-related and may be described by users as a 'jittery' feeling.


Q: Does Notusin contain gluten, lactose, or common allergens?

Notusin contains the active ingredient along with inactive ingredients (excipients). While the core drug may not contain common allergens, checking the specific inactive ingredient list on product packaging or consulting a pharmacist is necessary for managing allergy concerns.


Q: Can Notusin be crushed or chewed if someone has trouble swallowing pills?

Regulatory guidance indicates that solid dosage forms like softgel capsules should be swallowed whole, and lozenges must be dissolved slowly. In general, tablets and capsules are not recommended to be cut, crushed, or chewed unless the specific product label or a healthcare professional authorizes this.

How should Notusin be stored and disposed of?

How to Store and Dispose of Notusin

The official regulatory labeling defines specific conditions for storing and disposing of Notusin (Dextromethorphan Hydrobromide).

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, 20°C to 25°C (68°F to 77°F). Avoid excessive heat, such as temperatures above 40°C, and do not refrigerate.
Container Keep the medicine in its original container and ensure the container is tightly closed.
Handling The product should be stored out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Notusin should primarily utilize a community-based drug take-back program. If a program is unavailable, the medicine can be mixed with an unappealing substance (like dirt or used coffee grounds), sealed in a bag or container, and discarded in the household trash. The labeling advises against flushing the product down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Notusin found in:

A-Z Index: